Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2015 · 10-Q
Revenue$63.63M$63.63M+18.1% vs Q1 2014 Net Income-$21.52M-$21.52MN/M vs Q1 2014 EPS Diluted-$0.57-$0.57N/M vs Q1 2014 Gross Profit-$21,895,000— Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flow-$65,873,000N/M Free Cash Flowderived-$74,955,000N/M Margins · derivedGross margin-34.4%
Operating margin-44.5%+2.8 pt vs Q1 2014
Net margin-33.8%+3.7 pt vs Q1 2014
ended Mar 31, 2015 · filed May 8, 2015 · 38 d after period end